When CD8+ T cells from OTI TCR transgenic mice were activated in vitro and injected intravenously into C57BL/6 mice on day 10 after transplantation of E.G7-OVA-MOCK, tumor progression was suppressed (Fig. 4A). The gene discussed is CD8A; the disease is neoplasm.